Drugs / Lactobacillus salivarius UCC118
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT00510978 Comparator | Jan 2002 → Nov 2007 | Crohn disease, ulcerative colitis | University College Cork | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus salivarius UCC118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00510978 ↗ |
| Modality | Other / unclassified | “Lactobacillus salivarius UCC118 was chosen for its probiotic potential based on in vitro activity against several pathogens and several other properties including acid/bile tolerance.” NCT00510978 ↗ |
| Route | Oral | “milk or yoghurt may be used as a vehicle for delivery of Lactobacillus salivarius UCC118 to the gastrointestinal tract with equal efficacy in altering gut flora and apparent...” NCT00510978 ↗ |